IRIS
MUTTI, LUCIANO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.248
AS - Asia 2.254
EU - Europa 1.454
SA - Sud America 337
Continente sconosciuto - Info sul continente non disponibili 151
AF - Africa 43
AN - Antartide 1
Totale 8.488
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.152
SG - Singapore 1.073
RU - Federazione Russa 619
CN - Cina 428
HK - Hong Kong 378
IE - Irlanda 332
BR - Brasile 279
VN - Vietnam 199
IT - Italia 180
FR - Francia 121
CA - Canada 56
GB - Regno Unito 50
DE - Germania 45
IN - India 32
FI - Finlandia 28
BD - Bangladesh 23
MX - Messico 22
JP - Giappone 19
AR - Argentina 17
TR - Turchia 17
ES - Italia 14
SE - Svezia 14
IQ - Iraq 13
ZA - Sudafrica 13
NL - Olanda 11
CO - Colombia 10
PL - Polonia 10
ID - Indonesia 8
MY - Malesia 8
SA - Arabia Saudita 8
UZ - Uzbekistan 8
PK - Pakistan 7
UA - Ucraina 7
VE - Venezuela 7
BE - Belgio 6
EC - Ecuador 6
MA - Marocco 6
PY - Paraguay 6
AE - Emirati Arabi Uniti 5
KE - Kenya 5
LT - Lituania 5
AZ - Azerbaigian 4
CL - Cile 3
EG - Egitto 3
HN - Honduras 3
JO - Giordania 3
KR - Corea 3
NP - Nepal 3
OM - Oman 3
PE - Perù 3
PR - Porto Rico 3
SN - Senegal 3
TN - Tunisia 3
CR - Costa Rica 2
CZ - Repubblica Ceca 2
GR - Grecia 2
KG - Kirghizistan 2
NG - Nigeria 2
NI - Nicaragua 2
PH - Filippine 2
SR - Suriname 2
TH - Thailandia 2
TT - Trinidad e Tobago 2
UY - Uruguay 2
ZW - Zimbabwe 2
AM - Armenia 1
AO - Angola 1
AQ - Antartide 1
AT - Austria 1
BB - Barbados 1
BN - Brunei Darussalam 1
BO - Bolivia 1
BW - Botswana 1
BY - Bielorussia 1
CD - Congo 1
CH - Svizzera 1
CU - Cuba 1
DZ - Algeria 1
GP - Guadalupe 1
GT - Guatemala 1
GY - Guiana 1
IL - Israele 1
JM - Giamaica 1
KH - Cambogia 1
LB - Libano 1
LV - Lettonia 1
MD - Moldavia 1
ME - Montenegro 1
PS - Palestinian Territory 1
RS - Serbia 1
RW - Ruanda 1
SC - Seychelles 1
SI - Slovenia 1
SV - El Salvador 1
Totale 8.337
Salva come PNG Salva come JPEG
Città #
San Jose 778
Singapore 584
Dallas 394
Ashburn 372
Hong Kong 367
Santa Clara 337
Dublin 331
Council Bluffs 242
Boardman 192
The Dalles 174
Moscow 140
Lauterbourg 110
Hefei 83
Beijing 82
Los Angeles 82
Assago 76
New York 75
Ho Chi Minh City 56
Hanoi 52
Phoenix 40
Atlanta 27
São Paulo 27
Brooklyn 26
Chicago 23
Tokyo 19
Montreal 18
Da Nang 17
Falkenstein 16
Orem 16
Munich 14
Stockholm 14
Columbus 13
Helsinki 13
Milan 13
Rome 13
San Francisco 13
Chennai 12
Boston 11
Lappeenranta 11
L’Aquila 11
Mexico City 11
Denver 10
Manchester 10
Seattle 10
Toronto 10
Warsaw 10
London 9
Buffalo 8
Charlotte 8
Johannesburg 8
Ninh Bình 8
Rio de Janeiro 8
Amsterdam 7
Tashkent 7
Erbil 6
Florence 6
Frankfurt am Main 6
Houston 6
Shanghai 6
Ankara 5
Calgary 5
Dhaka 5
Guangzhou 5
Nairobi 5
Piscataway 5
Pittsburgh 5
Poplar 5
Secaucus 5
Washington 5
Baku 4
Bari 4
Brussels 4
Bắc Ninh 4
Curitiba 4
Haiphong 4
Hangzhou 4
Kansas City 4
Karachi 4
Manhuaçu 4
Mumbai 4
Ottawa 4
Paris 4
Philadelphia 4
Querétaro 4
Recife 4
Riyadh 4
Turku 4
Acalanes Ridge 3
Amman 3
Baghdad 3
Belo Horizonte 3
Biella 3
Biên Hòa 3
Brasília 3
Bến Tre 3
Campinas 3
Clifton 3
Dakar 3
Goiânia 3
Hải Dương 3
Totale 5.209
Salva come PNG Salva come JPEG
Nome #
Repurposing atovaquone: Targeting mitochondrial complex III and OXPHOS to eradicate cancer stem cells 966
PD-1/PD-L1 immune-checkpoint blockade induces immune effector cell modulation in metastatic non-small cell lung cancer patients: A single-cell flow cytometry approach 99
Intratumor microbiota as a novel potential prognostic indicator in mesothelioma 94
Comparison of 3 Randomized Clinical Trials of Frontline Therapies for Malignant Pleural Mesothelioma 94
{CONFIRM} trial: what is the real efficacy of second-line immunotherapy in mesothelioma? 93
Analysis of new treatments proposed for malignant pleural mesothelioma raises concerns about the conduction of clinical trials in oncology 92
Medical and Surgical Care of Patients With Mesothelioma and Their Relatives Carrying Germline BAP1 Mutations 88
European Respiratory Society Guideline on various aspects of quality in lung cancer care 84
The role of brain radiotherapy for EGFR- and ALK-positive non-small-cell lung cancer with brain metastases: a review 84
TNF-α determination in serum and pleural effusion in patients with lung cancer 83
The function and clinical implication of YTHDF1 in the human system development and cancer 81
A Drug Screening Revealed Novel Potential Agents against Malignant Pleural Mesothelioma 77
Comparing Addition of Radiotherapy in EGFR- and ALK-Positive NSCLC With Brain Metastases: Are We Evaluating the Optimal End Point? 77
P53 modeling as a route to mesothelioma patients stratification and novel therapeutic identification 75
Neuro–Immune Interactions in Severe COVID-19 Infection 75
HLA-B*44 and C*01 Prevalence Correlates with Covid19 Spreading across Italy 74
The function and clinical implication of circular RNAs in lung cancer 72
Abemaciclib for malignant pleural mesothelioma 71
Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: An open-label, single-arm, phase 2 trial 70
Association of SV40 with human tumours 70
Identification and Validation of Long Non-Coding RNA LCIIAR as a Biomarker in LUAD 69
Antitumoral effects of Bortezomib in malignant mesothelioma: evidence of mild endoplasmic reticulum stress in vitro and activation of T cell response in vivo 68
Chemoprevention of asbestos-linked cancers: A systematic review 68
Gefitinib targets EGFR dimerization and ERK1/2 phosphorylation to inhibit pleural mesothelioma cell proliferation 68
Genetic susceptibility to malignant mesothelioma and exposure to asbestos: The influence of the familial factor 67
Crossing survival curves of KEYNOTE-177 illustrate the rationale behind combining immune checkpoint inhibition with chemotherapy 65
Over-Expression of Long Non-Coding RNA-AC099850.3 Correlates With Tumor Progression and Poor Prognosis in Lung Adenocarcinoma 65
Simian virus-40 sequences are a negative prognostic cofactor in patients with malignant pleural mesothelioma 64
Preclinical Demonstrations of Synergistic Active Nutrient/Drug (and) Combination as a Potential Treatment for Malignant Pleural Mesothelioma 63
Based on the Real-World Results From Australia, Immunotherapy Is Not a Good Option for Patients With Mesothelioma 63
Interleukin-2 induces cell cycle perturbations leading to cell growth inhibition and death in malignant mesothelioma cells in vitro 62
CDK4, CDK6/cyclin‐d1 complex inhibition and radiotherapy for cancer control: A role for autophagy 61
Differential regulation of cell death pathways by the microenvironment correlates with chemoresistance and survival in leukaemia 60
Simian virus 40 and malignant mesothelioma (Review) 60
Erionite and asbestos differently cause transformation of human mesothelial cells 60
Malignant mesothelioma in 2004: How advanced technology and new drugs are changing the perspectives of mesothelioma patients. Highlights from the VII th Meeting of the International Mesothelioma Interest Group 60
Inhibition of the platelet-derived growth factor receptor beta (PDGFRB) using gene silencing, crenolanib besylate, or imatinib mesylate hampers the malignant phenotype of mesothelioma cell lines 60
A molecular epidemiology case control study on pleural malignant mesothelioma 59
What can independent research for mesothelioma achieve to treat this orphan disease? 59
Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma 59
Epigallocatechin-3-gallate induces mesothelioma cell death via H2O2-dependent T-type Ca2+ channel opening 58
Editorial: Prognostic factors in non-small cell lung cancer 58
When Ron met Tam in mesothelioma: All druggable for one, and one drug for all? 58
Prognostic significance of presence and reduplication of basal lamina in malignant pleural mesothelioma 57
In vivo effect of human granulocyte-macrophage colony-stimulating factor (GM-CSF) on neutrophil GM-CSF receptors 57
Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma 57
Erratum: Simian virus-40 sequences are a negative prognostic cofactor in patients with malignant pleural mesothelioma (Genes, Chromosomes and Cancer (2000) 29 (173-179)) 57
Blood cell redistribution in the lung after administration of recombinant human granulocyte-macrophage colony-stimulating factor 57
Recurrent chromosome 6 abnormalities in malignant mesothelioma 56
Editorial: Editor's challenge: Dr. Luciano Mutti - what is the true impact of ICIs on survival in the treatment of thoracic malignancies? 56
Comparison between plasma and serum osteopontin levels: Usefulness in diagnosis of epithelial malignant pleural mesothelioma 56
Targeting hypoxic response for cancer therapy 55
Sirtuin Family Members Selectively Regulate Autophagy in Osteosarcoma and Mesothelioma Cells in Response to Cellular Stress 55
Encouraging Fussy Eaters in EGFR-Mutated Lung Cancer 55
A common polymorphism within MSLN affects miR-611 binding site and soluble mesothelin levels in healthy people 55
Promising investigational drug candidates in phase I and phase II clinical trials for mesothelioma 54
Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer 54
Basic fibroblast growth factor in mesothelioma pleural effusions: correlation with patient survival and angiogenesis 54
Imatinib mesylate enhances therapeutic effects of gemcitabine in human malignant mesothelioma xenografts 53
Will antiangiogenic agents be a future for mesothelioma therapy? 53
Variations in aspecific bronchial reactivity elicited by methacholine in chronic bronchitis patients treated with doxofylline. Double blind cross-over study versus theophylline slow-release 52
SV40 and human brain tumors [2] 52
Simian virus 40 sequences in blood specimens from healthy individuals of Casale Monferrato, an industrial town with a history of asbestos pollution 52
Palliative and therapeutic activity of IL-2 immunotherapy in unresectable malignant pleural mesothelioma with pleural effusion: Results of a phase II study on 31 consecutive patients 52
Cancer testis antigens expression in mesothelioma: Role of DNA methylation and bioimmunotherapeutic implications 52
HLA Expression Correlates to the Risk of Immune Checkpoint Inhibitor-Induced Pneumonitis 51
New standard for assessing asbestos exposure and its consequences? 51
Risk of malignant pleural mesothelioma and polymorphisms in genes involved in the genome stability and xenobiotics metabolism 50
Study of the combined role of asbestos and SV40 in the pathogenesis of malignant mesothelioma 50
Estrogen receptor β exerts tumor repressive functions in human malignant pleural mesothelioma via EGFR inactivation and affects response to Gefitinib 50
Distinctive role of the systemic inflammatory profile in non-small-cell lung cancer younger and elderly patients treated with a pd-1 immune checkpoint blockade: A real-world retrospective multi-institutional analysis 50
Raltitrexed-Oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patients 50
New agents in the management of advanced mesothelioma 50
Expression of glycoprotein 90K in human malignant pleural mesothelioma: Correlation with patient survival 50
Evaluation of a series of serum mesothelin in patients with pleural Malignant Mesothelioma 49
Human mesothelioma cells exhibit tumor cell-specific differences in phosphatidylinositol 3-kinase/AKT activity that predict the efficacy of Onconase 49
Response to chemotherapy is predictive in relation to longer overall survival in an individual patient combined-analysis with pleural mesothelioma 49
Taurolidine and oxidative stress: A rationale for local treatment of mesothelioma 49
In arrayed ranks array technology in the study of mesothelioma steven 48
BAP1 status determines the sensitivity of malignant mesothelioma cells to gemcitabine treatment 48
SV40-dependent AKT activity drives mesothelial cell transformation after asbestos exposure 48
SV40 enhances the risk of malignant mesothelioma among people exposed to asbestos: A molecular epidemiologic case-control study 48
Bortezomib inhibits nuclear factor-κB-dependent survival and has potent in vivo activity in mesothelioma 47
Estrogen receptor β activation impairs mitochondrial oxidative metabolism and affects malignant mesothelioma cell growth in vitro and in vivo 47
Simian Virus 40 is not a cofactor in the pathogenesis of environmentally induced malignant pleural mesothelioma in Turkey 47
Establishment of four new mesothelioma cell lines: Characterization by ultrastructural and immunophenotypic analysis 47
Evidence for and implications of SV40-like sequences in human mesotheliomas and osteosarcomas 47
“Cancer Bio-Immunotherapy in Siena”: Eleventh Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 17–19, 2013 46
SV40 replication in human mesothelial cells induces HGF/Met receptor activation: A model for viral-related carcinogenesis of human malignant mesothelioma 46
MicroRNA signature of malignant mesothelioma with potential diagnostic and prognostic implications 45
Translational therapies for malignant pleural mesothelioma 45
The presence of simian-virus 40 sequences in mesothelioma and mesothelial cells is associated with high levels of vascular endothelial growth factor 45
Polymorphisms of glutathione-S-transferase M1 and manganese superoxide dismutase are associated with the risk of malignant pleural mesothelioma 45
Scientific Advances and New Frontiers in Mesothelioma Therapeutics 45
Ranpirnase and its potential for the treatment of unresectable malignant mesothelioma 45
Sustained expression of steroid receptor coactivator SRC-2/TIF-2 is associated with better prognosis in malignant pleural mesothelioma 44
Expression status of candidate genes in mesothelioma tissues and cell lines 44
Genetic susceptibility to malignant pleural mesothelioma and other asbestos-associated diseases 43
Malignant mesothelioma as both a challenge and an opportunity 43
Liquid biopsies from pleural effusions and plasma from patients with malignant pleural mesothelioma: A feasibility study 43
Totale 6.808
Salva come PNG Salva come JPEG
Categoria #
all - tutte 45.849
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 45.849
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2022/2023395 0 0 0 0 0 0 0 53 327 0 4 11
2023/2024354 7 13 18 55 19 141 0 7 3 26 24 41
2024/20252.387 176 28 153 30 215 266 240 109 658 119 235 158
2025/20264.101 172 455 333 396 317 237 933 154 368 360 351 25
2026/20271.251 1.039 212 0 0 0 0 0 0 0 0 0 0
Totale 8.488